Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isonicotinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.94 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.52 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isonicotinic Acid SCHEMBL1025948 | 1.00 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL1108 | 0.97 | — | — | |
| Isonicotinic Acid SCHEMBL1414914 | 0.97 | NAPRT (1.00) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25271512 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25219686 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25261208 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25270920 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL15401690 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25273146 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 | |
| Isonicotinic Acid SCHEMBL25222705 | 0.94 | NAPRT (0.94) | NAPRTMEN1KMT2ATSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039961-B | Capsule gel breaker for oilfield fracturing and preparation method and application thereof | 东营施普瑞石油工程技术有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119264298-A | Preparation method of antibacterial and antioxidant phenolic chitosan biquaternary ammonium salt | 安康学院 | 2025-01-07 | — | — | CN | claimed |
| CN-119039961-A | Capsule gel breaker for oilfield fracturing and preparation method and application thereof | 东营施普瑞石油工程技术有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-113429349-B | Preparation method of heterogeneous catalytic 2-trifluoromethyl substituted benzimidazole compound | 杭州职业技术学院 | 2022-12-20 | — | — | CN | claimed |
| CN-111732537-A | Preparation method of isoniazid | 沈阳双鼎制药有限公司 | 2020-10-02 | — | — | CN | claimed |
| CN-111138354-A | Preparation method of isoniazid | 沈阳双鼎制药有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-104785302-B | Denitrifying catalyst with selective catalytic reduction and its preparation method and application | 北京大学包头创新研究院 | 2019-05-10 | — | — | CN | claimed |
| WO-2018063010-A9 | NOVEL LUPEOL DERIVATIVE AND THE METHOD OF OBTAINING THE NOVEL LUPEOL DERIVATIVE | Politechnika Krakowska im.Tadeusza Kościuszki (PL) | 2018-05-24 | — | — | WO | claimed |
| WO-2018063010-A1 | NOVEL LUPEOL DERIVATIVE AND THE METHOD OF OBTAINING THE NOVEL LUPEOL DERIVATIVE | Politechnika Krakowska im.Tadeusza Kościuszki (PL) | 2018-04-05 | — | — | WO | claimed |
| CN-104785302-A | Selective catalytic reduction denitration catalyst, preparation method and application thereof | BAOTOU INST OF INNOVATION PEKING UNIVERSITY | 2015-07-22 | — | — | CN | claimed |
| CN-101891709-B | 5-halogenated methyl-1,2,3-thiadiazole compound and preparation method and use thereof | UNIV NANKAI | 2012-11-21 | — | — | CN | claimed |
| JP-63150280-A | — | — | None | — | — | JP | disclosed |
| JP-62161761-A | — | — | None | — | — | JP | disclosed |
| JP-63057570-A | — | — | None | — | — | JP | disclosed |
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-4069334-A | DIURETICS, HYPOTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1978-01-17 | — | — | US | disclosed |
| US-4003909-A | [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters | E. R. SQUIBB & SONS, INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-4002641-A | DIURETICS, SALURETICS, HYPOTENSIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
| US-3983233-A | ANTIINFLAMMATORY | AB BOFORS (SW) | 1976-09-28 | — | — | US | disclosed |
| US-3939162-A | Anthrapyrimidine dyes | BASF AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552796-B2 | EED inhibitor, and preparation method therefor and use thereof | HSD11B1, CYP4A11, CYP8B1 | CA2 822/4885GAA 2209/4885DRD1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.